Moderna, Inc.

MRNA | Nasdaq | CIK: 0001682852 | SIC: 2836 Biological Products, (No Diagnostic Substances) | active
Moderna is a biotechnology company and pioneer in mRNA medicine, focused on developing vaccines and therapeutics across infectious disease, oncology, and rare disease. The company currently markets three commercial products: Spikevax and mNEXSPIKE (COVID-19 vaccines) and mRESVIA (RSV vaccine). In 2025, Moderna generated $1.9 billion in total revenue, primarily from COVID vaccine sales, while advancing a broader pipeline including individualized cancer therapies.
infectious-disease-vaccinesoncology-therapeuticsrare-disease-therapeuticsrespiratory-vaccinesindividualized-cancer-therapymrna-medicine-platformindividualized-neoantigen-therapy
AI agents: Get this data as structured JSON (~200 tokens):
https://origin.rootz.global/api/company/MRNA
Profile | Timeline | SEC Filings | People

Products

NameTypeDescription
SpikevaxhardwareModerna's COVID-19 mRNA vaccine, one of its primary commercial products.
mNEXSPIKEhardwareModerna's COVID-19 vaccine launched commercially in Q3 2025, now leading product in U.S. retail channel.
mRESVIAhardwareModerna's mRNA-based vaccine against respiratory syncytial virus (RSV).
intismeran autogene (mRNA-4157)platformIndividualized mRNA-based neoantigen therapy for cancer, uniquely manufactured per patient, in Phase 2/3 trials.
mRNA-4359platformOncology pipeline candidate being advanced by Moderna.

Partnerships

PartnerTypeDescription
MerckdevelopmentCo-developing intismeran autogene (mRNA-4157) in combination with pembrolizumab (KEYTRUDA) across multiple tumor types in Phase 2 and Phase 3 trials.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/MRNA/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub